靶向恶性疟原虫血症期抗原的抗体与疟疾感染及疾病抵抗相关
在肯尼亚高流行区对266名2–7岁儿童进行3年纵向随访,每周评估健康、每月采集血样检测恶性疟原虫感染和IgG抗体。高水平的抗PfGBP130和抗PfGARP抗体与较低寄生虫密度及临床疟疾风险降低相关,而抗PfSEA-1抗体无此关联。
要点
- 高抗PfGBP130或抗PfGARP抗体水平与寄生虫密度分别降低3.4倍和1.9倍相关。
- 同时高水平的抗PfGBP130和抗PfGARP抗体与临床疟疾风险降低相关(HR 0.58)。
- 三年随访中,高抗体组平均临床疟疾发作4.51次,低抗体组7.11次。
核心结论
- 高水平的抗PfGBP130和抗PfGARP抗体可预测肯尼亚高流行区2–7岁儿童寄生虫密度降低和临床疟疾风险下降。
研究设计与样本
- 纵向队列研究,纳入肯尼亚西部高流行区266名2–7岁儿童,随访3年,每周评估健康状况,每月采集血样检测恶性疟原虫感染和抗体水平。
主要发现
- 抗PfGBP130或抗PfGARP抗体高水平的儿童寄生虫密度分别降低3.4倍和1.9倍(均P < 0.002)。
- 同时高水平的抗PfGBP130和抗PfGARP抗体与临床疟疾风险降低相关(HR: 0.58, 95% CI: 0.85-0.40)。
- 三年随访期间,高抗体组平均临床疟疾发作4.51次,低抗体组7.11次(P = 0.005)。
- 抗PfSEA-1抗体水平与寄生虫密度或临床疟疾风险无显著关联。
临床怎么用
- 抗PfGBP130和抗PfGARP抗体水平可作为评估儿童疟疾感染和发病风险的潜在生物标志物。
- 针对PfGBP130和PfGARP的血期疫苗候选抗原值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current licensed malaria vaccines are modestly protective against severe Plasmodium falciparum malaria but do not contain components which control blood stage infection. We evaluated the impact of antibodies to three blood stage candidate antigens (PfGARP, PfSEA-1, and PfGBP130) on P. falciparum infection and disease in a longitudinal cohort of children living in a holoendemic region of Western Kenya. METHODS: We enrolled and followed 266 children aged 2 to 7 years living in Western Kenya. Over the course of a 3-year follow-up period, we actively assessed their health status weekly, collected blood samples monthly to assess P. falciparum infection incidence and intensity, and measure IgG antibody levels to blood stage vaccine candidate antigens. RESULTS: Children with high levels of IgG antibodies to PfGBP130 or PfGARP, but not PfSEA-1, experienced 3.4- and 1.9- fold lower parasite densities respectively compared to those with low antibody levels (both P < 0.002). In addition, children with high levels of both anti-PfGBP130 and anti-PfGARP had significantly lower risk of clinical malaria compared to children with low antibody levels (HR: 0.58, 95% CI: 0.85-0.40). Over the 3-year follow-up period, individuals with elevated anti-PfGBP130 and anti-PfGARP antibody levels experienced an average of 4.51 cases of clinical malaria while those with lower levels experienced an average of 7.11 cases of clinical malaria (P = 0.005). CONCLUSIONS: Higher antibody levels to PfGBP130 and PfGARP predict significantly lower parasite densities and lower risks of clinical malaria among 2- to 7-year-old children residing in a holoendemic area of Kenya.
引用
- Park S, Pond-Tor S, Olewe F, et al. Antibodies targeting blood stage antigens of Plasmodium falciparum are associated with resistance to malaria infection and disease. Clin Infect Dis. 2026. PMID: 42695673. doi:10.1093/cid/ciag544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。